Reasonable and Necessary Medications in NDIS Claims: Funding and Entitlement
Understand NDIS Act Section 34 criteria and how to determine medication funding eligibility for NDIS participants.
Published: 4 April 2026
The NDIS Act 2013: What Medications Qualify as "Reasonable and Necessary"?
Under the National Disability Insurance Scheme Act 2013, section 34 defines "reasonable and necessary" supports as those that help the participant pursue their goals, are likely to be effective, and represent value for money. This legislative test applies equally to medications as to any other support type, yet medication funding in NDIS remains one of the most contested areas of participant entitlement.
The reason is conceptual: the NDIS is not a health insurance scheme. It is a social insurance scheme that funds supports related to a participant's disability, not the underlying health condition. This distinction shapes how medication funding decisions are made.
NDIS Medication Funding Scope: What Is and Is Not Covered
The boundary between NDIS-funded and non-NDIS-funded medications can be subtle. The table below outlines common scenarios:
| Medication Scenario | Likely NDIS Funding Position | Rationale |
|---|---|---|
| Daily antihypertensive or statin prescribed to prevent cardiovascular disease | Not funded by NDIS | General health maintenance unrelated to disability; typically funded by PBS for low income or private insurance |
| Anticonvulsant for seizure control in a participant with intellectual disability | Likely not funded by NDIS alone; may be concurrent with PBS | Seizure management is health care; however, NDIS may fund supports to manage the disability impact of seizures (e.g., supervision, safety equipment) |
| Antispasticity medication (baclofen, tizanidine) in a participant with cerebral palsy | Likely NDIS-funded if related to function and participation goals | Reduces spasticity-related functional impairment; helps participant engage in activities and rehabilitation |
| Antidepressant for mood disorder linked to disability adjustment | May be NDIS-funded if clearly linked to disability participation goals | NDIS may fund if treating symptoms that directly impede participation; less clear if depression is incidental comorbidity |
| Botulinum toxin injections for spasticity management | Likely NDIS-funded if improving function and participation | Reduces functional limitation; supports goal achievement and rehabilitation engagement |
| Medication for bowel or bladder management in spinal cord injury | Likely NDIS-funded | Manages disability-related functional impact; enables participation and social inclusion |
| Benzodiazepine for anxiety unrelated to disability | Not funded by NDIS | Health care for general mental health condition; outside disability-related support scope |
| Antibiotics for acute infection | Not funded by NDIS | Acute health care; typically covered by Medicare, health insurance, or participant cost |
The Section 34 Test: Four Questions for NDIS Medication Funding
When assessing whether a medication qualifies as a reasonable and necessary NDIS support, ask these four questions:
Question 1: Does This Medication Help the Participant Pursue Their NDIS Goals?
The participant's NDIS plan should document their goals: to return to work, improve social participation, develop independence skills, or enhance quality of life. Does the medication directly support pursuit of these goals? If a participant's goal is to increase employment hours but the medication causes sedation that interferes with work, the medication may not be supporting goal achievement. If a medication reduces pain or spasticity that was preventing the participant from attending vocational rehabilitation, it likely does support goal pursuit.
Question 2: Is the Medication Likely to Be Effective for the Intended Purpose?
There must be evidence that the medication works for its stated indication in this participant. This is not a blanket question about whether the drug is effective in general (it may be), but whether it is likely to be effective for this person's disability-related need. A trial period may be appropriate to establish effectiveness. If a participant has been on a medication for 12 months with no documented improvement in the functional outcome it was meant to address, effectiveness is in question.
Question 3: Does It Represent Value for Money Relative to the Participant's Disability Goals?
The NDIS is financially constrained and must steward public money carefully. A medication may be effective but if an alternative achieves the same outcome at lower cost, or if the NDIS funding could achieve better outcomes for the participant by supporting non-medication interventions (e.g., physiotherapy, psychology), the value-for-money test may not be met. This is not about being stingy; it is about directing resources where they create most benefit for the participant.
Question 4: Is This a Reasonable Use of NDIS Funding, or Should Another Scheme Bear the Cost?
This is the critical question that distinguishes NDIS funding from health insurance. If the medication is one that any person (not just a person with disability) might be prescribed for a health condition, it is fundamentally a health care cost, not a disability support cost. The PBS exists to subsidise essential medications for all Australians. Private health insurance and personal resources cover others. Is there a good reason the NDIS, rather than these other mechanisms, should fund this particular medication?
Common NDIS Medication Funding Disputes
Several medication categories generate recurring NDIS disputes. Understanding the agency's position on each helps you navigate these scenarios:
Antidepressants and Antipsychotics
Psychiatric medications are not automatically funded by NDIS. The NDIS funds supports to help participants manage the functional and participatory impact of their disability; treating a mental health condition is health care. The key distinction is whether the psychiatric symptoms are integral to the disability (e.g., anxiety directly related to autism and social participation) or concurrent with it. If a participant's depression is situational and unrelated to their primary disability diagnosis, NDIS is unlikely to fund it. If a participant's anxiety directly impedes their ability to engage in work or community activity due to their disability, NDIS may fund it as a disability-related support. The decision requires careful assessment of nexus.
Pain Medications
Pain management is particularly contentious. NDIS will generally not fund pain relief medications as substitutes for pain management therapies (physiotherapy, psychology-based interventions, pain management programs). However, if a medication (such as an antispasticity agent) reduces disability-related pain as a side effect of managing spasticity, and this improves function and participation, NDIS may fund it. The distinction is whether the medication is being used as a health care intervention for pain, or as an adjunct to disability-related support.
Benzodiazepines and Sedatives
NDIS is increasingly restricting benzodiazepine funding, particularly long-term use. These medications are health care for anxiety or insomnia, not disability supports. NDIS may fund short-term benzodiazepines during a crisis or transition period, but long-term benzodiazepine funding is inconsistent with NDIS principles and the agency's commitment to reduce inappropriate psychotropic use.
Medications for Comorbid Conditions
If a participant has both a primary disability (e.g., cerebral palsy) and a comorbid condition (e.g., type 2 diabetes), NDIS typically does not fund medications for the comorbidity. The comorbidity is treated through the mainstream health system, PBS, or private insurance. However, if the comorbid condition directly impacts the participant's ability to engage in their disability-related goals (e.g., diabetes management affecting ability to participate in day programs due to energy or attention issues), a stronger case for NDIS funding may exist.
When to Refer for Independent Pharmacy Review
NDIS participants and planners should consider independent pharmacy review in these scenarios:
- A participant is on multiple psychiatric medications and there is uncertainty about which, if any, are NDIS-reasonable supports versus health care costs
- A medication has been prescribed long-term without documented review or evidence of ongoing benefit for the stated disability-related goal
- A participant is on high-dose medication that may be masking underlying impairment and preventing engagement in active rehabilitation or therapy
- Alternative non-medication interventions may achieve the same outcome at lower cost or with better long-term outcomes for the participant
- There is dispute between the NDIS and participant (or participant's representative) about medication funding eligibility
- A medication has significant adverse effects impeding participation, and alternatives should be explored
The Broader Context: NDIS and Mainstream Health Care
A critical principle underlying NDIS medication policy is that the NDIS should not become a replacement health insurance scheme. Participants in the NDIS remain entitled to Medicare services, PBS subsidies, and other health care access like any Australian. Conflicts sometimes arise when a participant prefers NDIS funding to PBS funding (NDIS covers 100% versus PBS copayment), but the agency correctly enforces the principle that foundational health care is a mainstream responsibility.
As a claims manager in NDIS, your role is to assess whether medications proposed for funding genuinely meet the Section 34 test. When in doubt, raising the matter with the NDIS participant planner or seeking independent pharmacy review is entirely appropriate.
Documentation and Defensibility in NDIS Medication Decisions
Record the following in plan documentation:
- The participant's disability diagnosis and primary goals for the plan period
- Any medications currently prescribed, with indication and dose
- Assessment of each medication's link to disability-related goals and functional participation
- Any concerns identified (e.g., lack of evidence of benefit, potential for alternative interventions)
- Decision regarding NDIS funding (approved as disability-related support, not approved, approved with condition or review)
- If not approved, reference to alternative funding pathway (PBS, mainstream health care, private cost)
- Plan for review of medication effectiveness and ongoing necessity
This documentation protects the NDIS from challenge and clearly communicates to the participant why medication funding decisions have been made.
Navigating medication funding in NDIS can be complex. IMM's independent medication review service helps NDIS planners and participants clarify which medications are disability-related supports and which should be funded through mainstream health care.
Read the definitive guide to reasonable and necessary medications
